We finally have an RSV vaccine

It’s taken decades, but we now have a vaccine against respiratory syncytial virus (RSV). The disease most seriously affects young children and older adults, which are the two populations emerging vaccines are targeting. I spoke to scientists who developed the vaccine at GlaxoSmithKline—as well as several at other companies that are also making RSV shots—about why this landmark vaccine for people ages 60 and older has taken so long.

Here's what to know about the new shot, called Arexvy, and the long road to its milestone approval:

READ MORE